Follow
Natasha Leighl
Natasha Leighl
Medical Oncology, Princess Margaret
Verified email at uhn.ca
Title
Cited by
Cited by
Year
Pembrolizumab for the treatment of non–small-cell lung cancer
EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ...
New England Journal of Medicine 372 (21), 2018-2028, 2015
65082015
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline
JR Brahmer, C Lacchetti, BJ Schneider, MB Atkins, KJ Brassil, ...
Journal of Clinical Oncology 36 (17), 1714-1768, 2018
35602018
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer
DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ...
New England Journal of Medicine 376 (25), 2415-2426, 2017
25302017
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non–small-cell lung cancer: AVAiL
M Reck, J von Pawel, P Zatloukal, R Ramlau, V Gorbounova, V Hirsh, ...
Journal of Clinical Oncology 27 (8), 1227-1234, 2009
19482009
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
C Zimmermann, N Swami, M Krzyzanowska, B Hannon, N Leighl, A Oza, ...
The Lancet 383 (9930), 1721-1730, 2014
18382014
Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study
EB Garon, MD Hellmann, NA Rizvi, E Carcereny, NB Leighl, MJ Ahn, ...
Journal of Clinical Oncology 37 (28), 2518-2527, 2019
10502019
Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update
TJ Smith, K Bohlke, GH Lyman, KR Carson, J Crawford, SJ Cross, ...
Journal of Clinical Oncology 33 (28), 3199-3212, 2015
9142015
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III …
M Reck, J Von Pawel, P Zatloukal, R Ramlau, V Gorbounova, V Hirsh, ...
Annals of oncology 21 (9), 1804-1809, 2010
7842010
Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis
RG Hagerty, PN Butow, PM Ellis, EA Lobb, SC Pendlebury, N Leighl, ...
Journal of clinical oncology 23 (6), 1278-1288, 2005
7272005
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
SY Shen, R Singhania, G Fehringer, A Chakravarthy, MHA Roehrl, ...
Nature 563 (7732), 579-583, 2018
7262018
Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update
N Hanna, D Johnson, S Temin, S Baker Jr, J Brahmer, PM Ellis, ...
Journal of Clinical Oncology 35 (30), 3484-3515, 2017
6782017
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced …
T Reungwetwattana, K Nakagawa, BC Cho, M Cobo, EK Cho, A Bertolini, ...
Journal of Clinical Oncology 36 (33), 3290-3297, 2018
6652018
Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase–positive non–small-cell lung cancer: a randomized, multicenter phase II trial
DW Kim, M Tiseo, MJ Ahn, KL Reckamp, KH Hansen, SW Kim, RM Huber, ...
Journal of Clinical Oncology 35 (22), 2490-2498, 2017
6322017
Cancer patient preferences for communication of prognosis in the metastatic setting
RG Hagerty, PN Butow, PA Ellis, EA Lobb, S Pendlebury, N Leighl, ...
Journal of clinical oncology 22 (9), 1721-1730, 2004
5802004
Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes
JD McKay, RJ Hung, Y Han, X Zong, R Carreras-Torres, DC Christiani, ...
Nature genetics 49 (7), 1126-1132, 2017
5592017
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature
G D'Addario, M Pintilie, NB Leighl, R Feld, T Cerny, FA Shepherd
Journal of clinical oncology 23 (13), 2926-2936, 2005
4942005
Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology …
GP Kalemkerian, N Narula, EB Kennedy, WA Biermann, J Donington, ...
Journal of Clinical Oncology 36 (9), 911-919, 2018
4912018
Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non–small cell lung cancer
NB Leighl, RD Page, VM Raymond, DB Daniel, SG Divers, KL Reckamp, ...
Clinical cancer research 25 (15), 4691-4700, 2019
4872019
Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study
K Park, EB Haura, NB Leighl, P Mitchell, CA Shu, N Girard, S Viteri, ...
Journal of Clinical Oncology 39 (30), 3391-3402, 2021
4782021
Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials
M Di Maio, C Gallo, NB Leighl, MC Piccirillo, G Daniele, F Nuzzo, ...
Journal of Clinical oncology 33 (8), 910-915, 2015
4602015
The system can't perform the operation now. Try again later.
Articles 1–20